Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COMMENTARY
COMMENTARY
-
Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -2-
January 30, 2006
-
Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II) -1-
January 30, 2006
-
COMMENTARY 2 articles
January 30, 2006
-
JPLA SEMINAR
January 30, 2006
-
Maurer's Healthcare Insight (72)
January 30, 2006
-
From "Replacement" to "Addition": Prescription Form
January 23, 2006
-
Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) －２－
January 23, 2006
-
Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I) －１－
January 23, 2006
-
A Happy Year 2006 to Japanese Pharmaceutical Stocks!
January 23, 2006
-
Industry Should Insist on Brand Average Market Price Principle
January 16, 2006
-
The Bottom of the Tornado
January 16, 2006
-
＜New Year's commentary＞Looking at the Pharma Industry Backward from 2009 -1- Sugio Seko, President Pharma Marketing Survey Research Laboratory (December, 2005)
January 9, 2006
-
＜New Year's commentary＞Looking at the Pharma Industry Backward from 2009 -2- Sugio Seko, President Pharma Marketing Survey Research Laboratory (December, 2005)
January 9, 2006
-
Schrodinger's Cat
December 12, 2005
-
Top Wholesalers Cut Costs to Offset Declines in Gross Profits
December 5, 2005
-
Importance of Framing
November 21, 2005
-
A Cluster of Diseases - Metabolic Syndrome: Reflecting Aging Society
November 7, 2005
-
A Cluster of Diseases - Metabolic Syndrome:Reflecting an Aging Society -1-
October 31, 2005
-
Commentary 2005 Will Be "Year 1" of Japanese Drug Industry Reorganization
October 17, 2005
-
COMMENTARY 2 articles
October 10, 2005
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…